Wed, Apr 01|
Cinquecento Roman Trattoria
Utilizing a selective nuclear export inhibitor in relapsed refractory multiple myeloma
Time & Location
Apr 01, 2020, 6:00 PM
Cinquecento Roman Trattoria, 500 Harrison Ave, Boston, MA 02118, USA
About The Event
Presented by Suzy Graham, RN, BSN, OCN
Karyopharm Nurse Liaison
Please RSVP to Suzy as space is limited.
KAR0000677 Please reference this number during registration.
XPOVIO is indicated in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least 4 prior therapies and whose disease is refractory to at least 2 proteasome inhibitors, at least 2 immunomodulatory agents, and an anti- CD38 monoclonal antibody.
This indication is approved under accelerated approval based onresponserate.Continuedapprovalforthisindicationmaybe contingentuponverificationanddescriptionofclinicalbenefitin a confirmatory trial.
The most common adverse reactions (ARs) (incidence ≥20%) were thrombocytopenia, fatigue, nausea, anemia, decreased appetite, decreased weight, diarrhea, vomiting, hyponatremia, neutropenia, leukopenia, constipation, dyspnea, and upper respiratory tract infection.
The treatment discontinuation rate due to ARs was 27%. Reduction or interruption of XPOVIO dose occurred in 53% and 65.3% of patients, respectively. The most frequent ARs requiring permanent discontinuation in ≥ 4% of patients included fatigue, nausea, and thrombocytopenia. The rate of fatal ARs was 8.9%.